BridgeBio Oncology Therapeutics, Inc.

BBOT is a clinical-stage biotechnology company focused on developing therapies for patients with cancers driven by RAS and PI3Kα. These are frequently mutated oncogenes that contribute to uncontrolled tumor growth in cancers such as lung, breast, pancreas, and colon cancer. RAS mutations are found in approximately 30% of all human cancers. The company's pipeline includes three orally bioavailable small molecule inhibitors. These inhibitors are designed to achieve high levels of target inhibition against oncogenic drivers while maintaining a favorable tolerability profile. BBOT aims to provide significant benefit to patients beyond standard care, including potential benefits for KRAS mutant tumors through combination therapies. BBOT's programs, BBO-8520 (direct KRAS G12C ON/OFF) and BBO-11818 (direct panKRAS ON/OFF), target KRAS, which is the most mutated oncogene. KRAS is a protein that switches between an active "ON" state and an inactive "OFF" state. Oncogenic mutations in KRAS disrupt this balance, increasing the "ON" state and leading to uncontrolled cell growth and cancer progression. Most KRAS mutations occur in codon 12. In non-small cell lung cancer (NSCLC), KRAS G12C mutations are present in approximately 15% of patients. While the FDA approved the first KRAS G12C-targeting therapeutic in 2021, these first-generation drugs exclusively target the "OFF" state, which can lead to adaptive resistance and limit efficacy and durability. Patients treated with "OFF" state inhibitors also experience significant toxicities, which are worse when combined with immune checkpoint inhibitors (ICI).